Loading clinical trials...

UNKNOWN

COVID-19 and Hereditary Metabolic Diseases

Prospective Study on the Impact of COVID-19 on the Equilibrium of Hereditary Metabolic Disease (MHM) in Patients With or Who Have Contracted COVID-19

NCT04645498•University Hospital, Lille

View on ClinicalTrials.gov

Summary

No additional risk factors have been identified in patients with Inherited Metabolic Diseases (IMD) for contracting or presenting complications of COVID-19 compared to the general population. Yet, IMD patients have cell/tissue alterations that could constitute a potential direct or indirect target for the virus. We do not know the impact of this infection on patients suffering from MHM, nor the possible effect of specific treatment of MHM on the evolution of COVID-19. This study will collect French IMD patients having or having had COVID-19 infection. The main objective is to estimate among IMD patients contracting COVID-19 the frequency of disease aggravation or metabolic decompensation. The secondary objectives will be : a. to evaluate the incidence of COVID-19 diagnosed in a given group of IMD when the number of patients with this IMD is known (Urea Cycle Deficiency, Gaucher Disease). b. to evaluate the impact of IMD on the and severity of COVID-19 infection

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Child or adult patient with a diagnosis of IMD
•Symptomatic or asymptomatic patient tested positive for COVID-19 (PCR and/or serology)
•Symptomatic patient non tested but with strong clinical suspicion for COVID-19
•Patient affiliated with the health insurance

Exclusion Criteria

•inability to receive informed information
•Persons deprived of liberty

Locations (1)

Hop Claude Huriez Chu Lille

Lille, France

Key Dates

Start Date

February 1, 2021

Primary Completion Date

February 1, 2023

Completion Date

February 1, 2023

Last Updated

March 2, 2022

Enrollment

ESTIMATED participants

Conditions

Covid19Metabolism, Inborn Errors

Contacts

Claire Douillard, MD

CONTACT

0320445962 claire.douillard@chru-lille.fr

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 2, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

COVID-19 and Hereditary Metabolic Diseases

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy